Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression.

about

Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression.

Item

http://www.wikidata.org/entity/Q35854185

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Treatment of a mouse model of ...... effect on disease progression.

@ast

Treatment of a mouse model of ...... effect on disease progression.

@en

type

Item

label

Treatment of a mouse model of ...... effect on disease progression.

@ast

Treatment of a mouse model of ...... effect on disease progression.

@en

prefLabel

Treatment of a mouse model of ...... effect on disease progression.

@ast

Treatment of a mouse model of ...... effect on disease progression.

@en

P1476

Treatment of a mouse model of ...... effect on disease progression

@en

P2093

Hsu-Wen Tseng

http://www.w3.org/2001/XMLSchema#string

Katelin R Haynes

http://www.w3.org/2001/XMLSchema#string

Matthew A Brown

http://www.w3.org/2001/XMLSchema#string

Michaela Kneissel

http://www.w3.org/2001/XMLSchema#string

Tibor T Glant

http://www.w3.org/2001/XMLSchema#string

P2860

Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

WNT signaling in bone homeostasis and disease: from human mutations to treatments

High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage

Enzyme replacement therapy for murine hypophosphatasia

Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis.

A longitudinal study on an autoimmune murine model of ankylosing spondylitis.

Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.

Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitors

P2888

s12891-015-0823-8

P304

368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12891-015-0823-8

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gethin Thomas

P577

2015-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284770808

http://www.w3.org/2001/XMLSchema#string

P6179

1034093201

http://www.w3.org/2001/XMLSchema#string

P698

26612313

http://www.w3.org/2001/XMLSchema#string

P932

4662039

http://www.w3.org/2001/XMLSchema#string